|
|
News Breaks | | | | July 3, 2012 | | 08:44 EDT |  | BLRX | BioLineRx initiated with a Buy at Roth Capital
Target $4. | |
|
News For BLRX From The Last 14 Days Check below for free stories on BLRX the last two weeks. |
|
|
| June 10, 2013 | | 07:10 EDT |  | BLRX | BioLineRx signs out-licensing agreement with CTTQ for hep C drug
 Subscribe for More Information | | | June 6, 2013 | | 07:06 EDT | | BLRX | BioLineRx enrolls first patient in Phase 2 trial for leukemia candidate BL-8040
BioLineRx enrolled the first U.S. patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia. The company has also recently received regulatory approval from the Israeli Ministry of Health to conduct the trial in Israel. The activation of Israeli sites is anticipated during the next few weeks. The study is designed to evaluate the safety and efficacy profile of repeated escalating doses of BL-8040 in adult subjects with relapsed or refractory AML. Up to 50 patients are expected to be enrolled in the study, which is expected to be conducted at 8 sites in the U.S. and Israel. | |
|
|
|
|
|
|
